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Background: Diabetes mellitus (DM) patients have increased thromboxane A2 (TXA2) which activate TX prostanoid receptors (TPR). In DM patients, 
EV-077, a combined TXA2 synthase inhibitor and TPR antagonist, achieves more effective platelet inhibition compared with aspirin. However, the 
effects of EV-077 in DM patients treated with clopidogrel remain unknown.
methods: In this pilot pharmacodynamic (PD) study the effects of EV-077 on platelet signaling in DM patients (n=10) with stable atherosclerotic 
disease on aspirin 81mg/day were assessed. Patients were switched to clopidogrel (75mg/day) monotherapy for 7-10 days. LTA with in 
vitro incubation of vehicle and EV-077 (100nM) was performed. Arachidonic acid (AA, 1mM), collagen (3 µg/ml), and a stable TXA2 analog 
(U-46619,7µM), were used as makers of non-purinergic signaling, and ADP (5µM and 20µM) measured purinergic signaling.
results: In clopidogrel treated patients, EV-077 reduced non-purinergic mediated pathways of platelet activation, leading to near complete 
blockade of TXA2 mediated platelet activation following AA and U-46619 stimuli (Table). Notably, EV-077 also reduced purinergic mediated platelet 
activation, suggesting a synergistic effect and interplay between these signaling pathways (Table). 
In vitro PD effects of EV-077
Clopidogrel Clopidogrel+EV-077 p-value
Non-purinergic
(LTA, %)
AA (1mM) 49.7±28.2 1.2±1.6 0.009
U-46619 (7μΜ) 71.6±11.6 0.9±0.9 0.005
Collagen (3μg/mL) 72.6±10.2 30.1±18.1 0.005
Purinergic
(LTA, %)
ADP (5μM) 32.8±17.2 22.8±12.4 0.009
ADP (20μM) 54.8±13.3 44.3±12.3 0.01
conclusions: More effective blockade of TXA2 mediated platelet activation with EV-077 is associated with enhanced inhibition of purinergic and 
non-purinergic signaling pathways in DM patients while on clopidogrel monotherapy.
